Drug intelligence / Profile preview

tutin + hyenanchin

Development stage
Unknown
Modality
Small Molecules
Administration
Oral (main Risk Route: Dietary Ingestion Via Contaminated Foods, Especially Honey)[1][2][5]
01

Overview

**Tutin + hyenanchin** is a combination of two structurally related neurotoxic sesquiterpene lactones, both naturally occurring plant toxins. Tutin is most famously derived from several plants such as *Coriaria* species and *Hyaenanche globosa*, while hyenanchin is commonly isolated from *Hyaenanche globosa*. They are both potent neurotoxins known for their ability to antagonize inhibitory neurotransmission in the central nervous system. Tutin and hyenanchin act primarily as **non-competitive antagonists of the GABAA receptor**, blocking the main inhibitory pathway in the mammalian brain and resulting in CNS stimulation, convulsions, and potentially death in higher doses. Both have been implicated in the toxicity associated with contaminated honeys in New Zealand and are known to evoke epileptiform activity and convulsions in animal models. In addition to GABAA antagonism, tutin also inhibits glycine receptors in the spinal cord and possibly other ligand-gated ion channels. Cytotoxicity and some anti-cancer activity in vitro have been described, but their primary relevance is toxicological, not therapeutic. There are no established pharmaceutical uses, primary indications, developers, or manufacturers for this combination, and no evidence supports their appropriateness as medicines[1][2][3][5].

02

Targets

Glycine receptorGABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on tutin + hyenanchin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tutin + hyenanchin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call